[Series] Management of prematurity-associated lung disease from infancy through to adulthood

Preterm birth has lifelong pulmonary consequences, with many individuals developing prematurity-associated lung disease (PLD). This third paper in the prematurity-associated lung disease Series summarises current evidence for treatment and monitoring of PLD and its phenotypes. Preventive strategies, including maternal and infant vaccination to reduce early life viral exposures, are emerging as key interventions. Pharmacological approaches, such as inhaled corticosteroids, alone or combined with long-acting bronchodilators, show potential benefits in childhood, although there is currently little evidence on phenotype-specific responses.